Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
HemoGenyx Pharmaceuticals Plc ( (GB:HEMO) ) just unveiled an update.
Hemogenyx Pharmaceuticals plc announced that all resolutions were passed at its Annual General Meeting, reflecting strong shareholder support. This outcome is expected to positively impact the company’s governance and operational strategies, reinforcing its position in the biopharmaceutical industry.
More about HemoGenyx Pharmaceuticals Plc
Hemogenyx Pharmaceuticals plc is a clinical stage biopharmaceutical company headquartered in London, with US subsidiaries in New York City. The company focuses on developing new medicines and treatments for blood and autoimmune diseases, leveraging a platform technology for novel product development.
Average Trading Volume: 41,256
Technical Sentiment Signal: Sell
Current Market Cap: £7.72M
See more data about HEMO stock on TipRanks’ Stock Analysis page.